---
layout: default
title: Secretin Human
parent: 僅模型預測 (L5)
nav_order: 1149
evidence_level: L5
indication_count: 10
---

# Secretin Human
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Secretin Human: From [Indication Not Specified] to Open-Angle Glaucoma

## One-Sentence Summary

> Original indication data for Secretin Human is not available in this evidence pack, and its mechanism of action is also a data gap.
> The TxGNN model predicts a possible association with **Open-Angle Glaucoma**,
> but this is a **pure model-score prediction (L5)** — there are currently **no clinical trials and no literature** directly supporting this candidate, and the drug's own repurposing-rationale note flags it as a likely knowledge-graph false positive.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in evidence pack |
| Predicted New Indication | Open-Angle Glaucoma |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Market Status (Taiwan) | Not Marketed |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data (`original_moa`) is not available in DrugBank/evidence-pack form. Based on the mechanistic notes attached to this prediction, secretin is known to act as an agonist of the secretin receptor (SCTR), a class B GPCR expressed mainly in the exocrine pancreas and select central neurons. No literature or pathway data currently link SCTR signaling to aqueous humor production or outflow regulation in the eye.

The evidence pack's own repurposing-rationale explicitly assesses this prediction as **likely a false positive** arising from knowledge-graph clustering (e.g., shared GPCR-family nodes) rather than a genuine pharmacological connection to open-angle glaucoma. The same caveat applies to the other nine ranked candidates in this pack (hereditary glaucoma, hypotrichosis, alopecia, hypertrichosis, Dandy-Walker malformation, etc.) — none have an identifiable mechanistic link to secretin/SCTR biology, and rank #9 ("malformation syndrome with odontal/periodontal component") is only supported by 20 general periodontology papers that never mention secretin or SCTR, i.e., keyword/co-occurrence noise rather than drug-specific evidence.

Given the combination of a missing MOA, no supporting clinical or literature evidence, and an explicit false-positive flag in the source rationale, this candidate should be treated as exploratory/low-confidence rather than a validated repurposing signal.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Market Information

No license records are available — Secretin Human is currently **not marketed** under this regulatory dataset (0 licenses on file).

---

## Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are all marked as data gaps in this evidence pack; DG001 — TFDA label warnings/contraindications — is flagged as a **Blocking** gap, meaning safety review cannot proceed until this is resolved.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked candidate (open-angle glaucoma) has an evidence level of L5 — model score only, no clinical trials, no literature — and the evidence pack's own mechanistic analysis assesses it as a probable knowledge-graph artifact rather than a real pharmacological signal. No other ranked candidate in this pack fares better; several are explicitly flagged as mechanistically implausible or supported only by irrelevant literature.

**To proceed, the following is needed:**
- Resolve DG001 (Blocking): obtain TFDA/FDA label warnings and contraindications before any safety review can begin
- Resolve DG002: obtain confirmed mechanism of action (MOA) data from DrugBank to properly assess plausibility
- Independent pharmacological or preclinical evidence connecting SCTR signaling to intraocular pressure regulation, if this indication is to be pursued further
- If no such mechanistic or experimental support emerges, this candidate should be deprioritized in favor of higher-evidence-level candidates from other drugs
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

